Business Context and Reporting Period
Company: InMed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Report Date: September 9, 2022 (Event Date)
Closing Date: September 13, 2022
Context: The Company, an emerging growth company incorporated in British Columbia, announced and subsequently consummated a private placement of equity securities to raise capital.
Key Financial Metrics and Transaction Details
This filing details a capital raise rather than periodic operating results. Key financial figures related to the transaction include:
- Gross Proceeds: Approximately $6.0 million (before deducting placement agent fees and offering expenses).
- Offering Price: $8.68 per share (or pre-funded warrant).
- Securities Issued at Closing:
- 90,000 common shares.
- Pre-funded warrants to purchase 601,245 common shares (exercise price: $0.0001).
- Preferred investment options to purchase up to 1,382,490 common shares (exercise price: $8.44; 7-year term).
- Placement Agent Fees:
- Cash fee: 7.5% of aggregate gross proceeds.
- Management fee: 1.0% of gross proceeds.
- Warrants: Issued to the agent (H.C. Wainwright & Co., LLC) covering 6.5% of the aggregate number of shares placed (44,931 preferred investment options).
Note: The filing does not provide current revenue, profit, cash flow, margins, or debt levels. It focuses exclusively on the terms of the private placement.
Material Changes and Transaction Structure
The primary material change is the entry into a Material Definitive Agreement (Securities Purchase Agreement) and the subsequent issuance of unregistered equity securities.
- Investor Composition: Two institutional accredited investors participated in the purchase.
- Beneficial Ownership Limits: The agreement includes provisions allowing investors to elect pre-funded warrants or preferred investment options to avoid exceeding beneficial ownership thresholds of 4.99% or 9.99% of outstanding common shares.
- Registration Rights: The Company entered into a Registration Rights Agreement obligating it to file registration statements with the SEC for the resale of the issued securities.
- Extinguishment of Prior Options: One purchaser agreed to cancel previously issued preferred investment options covering 412,331 common shares.
Outlook, Risks, and Contingencies
Management Commentary: The filing incorporates press releases announcing the pricing and closing of the transaction but does not contain forward-looking guidance on product development or financial performance in this specific document.
Risks and Contingencies:
- Unregistered Securities: The common shares, pre-funded warrants, and preferred investment options were offered under Section 4(a)(2) of the Securities Act and Regulation D. They are not registered and may not be resold in the U.S. absent registration or an exemption.
- Dilution: The issuance of new shares and the potential exercise of warrants and options will result in dilution to existing shareholders.
- Exercise Restrictions: Holders are precluded from exercising options or warrants if doing so would cause them to exceed the specified beneficial ownership limits (4.99% or 9.99%).
Key Facts for Investor Verification
- Verify the net proceeds received by the Company after deducting the 7.5% placement fee, 1.0% management fee, and legal expenses.
- Confirm the total number of shares outstanding post-closing to assess the immediate dilution impact of the 90,000 shares and 601,245 pre-funded warrants.
- Review the Registration Rights Agreement (Exhibit 10.2) to understand the timeline for when the new shares can be publicly traded.
- Monitor the exercise of the 1,382,490 preferred investment options issued to investors and the 44,931 options issued to the placement agent, noting the $8.44 and $10.85 exercise prices respectively.
- Check subsequent filings for the use of the $6.0 million in proceeds, as this 8-K does not specify the allocation of funds.